Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study

Clark, Christopher M.; Pontecorvo, Michael J.; Beach, Thomas G.; Bedell, Barry J.; Coleman, Robert E.; Doraiswamy, P. Murali; Fleisher, Adam; Reiman, Eric M.; Sabbagh, Marwan N.; Sadowsky, Carl; Schneider, Julie A.; Arora, Ankit; Carpenter, Alan; Flitter, Matthew; Joshi, Abhinay D.; Krautkramer, Michael J.; Lu, Ming; Mintun, Mark A.; Skovronsky, Daniel

doi:10.1016/s1474-4422(12)70142-4

Cited by 694 publications

(608 citation statements)

References 19 publications

Supporting

Mentioning

570

Contrasting

Unclassified

Order By: Relevance

“…The former refers to the visual assessment made by a radiologist who based his or her interpretation using a reference of normality developed on the basis of his or her own experience. The latter refers to a structured assessment, for which image interpretation is based on detailed, clear, and specific instruction [11].…”

Section: Methodsmentioning

confidence: 99%

“…As expected, the number of responder centers in a country correlated with its estimated population (Spearman's r 5 .920, P , .005), under the hypothesis that if there is a bigger population then there will be more centers by demand of the population and thus likely more to respond. Amyloid-PET Cortical amyloid uptake Statistical maps [48] Structured visual assessment [11] Abbreviations: MR, magnetic resonance; FDG, fluorodeoxyglucose; PET, positron emission tomography; CSF, cerebrospinal fluid.…”

Section: Responders' Featuresmentioning

confidence: 99%

“…Considering all reported examinations, the most frequently used tools were visual rating for MR (61%) (i.e. Scheltens's MTA scale [12]); the traditional read for FDG-PET (70%); and structured visual assessment for amyloid-PET (80%) [11]. Eighteen percent (6/33) of responders rated cerebrovascular disease on MR with a number of different structured visual scales such as Fazekas's [13], Wahlund's [14], and Pasquier's [15].…”

Section: Use Of Biomarkers and Reading Tools 331 Imaging Biomarkersmentioning

confidence: 99%

See 2 more Smart Citations

The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey

Bocchetta

Galluzzi

Kehoe

et al. 2014

Alzheimer's & Dementia

View full text Add to dashboard Cite

We investigated the use of Alzheimer's disease (AD) biomarkers in European Alzheimer's Disease Consortium centers and assessed their perceived usefulness for the etiologic diagnosis of mild cognitive impairment (MCI). We surveyed availability, frequency of use, and confidence in diagnostic usefulness of markers of brain amyloidosis (amyloid positron emission tomography [PET], cerebrospinal fluid [CSF] Ab42) and neurodegeneration (medial temporal atrophy [MTA] on MR, fluorodeoxyglucose positron emission tomography [FDG-PET], CSF tau). The most frequently used biomarker is visually rated MTA (75% of the 37 responders reported using it "always/ frequently") followed by CSF markers (22%), FDG-PET (16%), and amyloid-PET (3%). Only 45% of responders perceive MTA as contributing to diagnostic confidence, where the contribution was rated as "moderate". Seventy-nine percent of responders felt "very/extremely" comfortable delivering a diagnosis of MCI due to AD when both amyloid and neuronal injury biomarkers were abnormal (P , .02 versus any individual biomarker). Responders largely agreed that a combination of amyloidosis and neuronal injury biomarkers was a strongly indicative AD signature.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Responders' Featuresmentioning

confidence: 99%

Section: Use Of Biomarkers and Reading Tools 331 Imaging Biomarkersmentioning

confidence: 99%

See 1 more Smart Citation

The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey

Bocchetta

Galluzzi

Kehoe

et al. 2014

Alzheimer's & Dementia

View full text Add to dashboard Cite

show abstract

“…Findings demonstrated a sensitivity and specificity of 92 % and 100 %, respectively, for detection of moderate-to-frequent plaques if scanned 2 years prior to autopsy, and a sensitivity and specificity of 96 % and 100 %, respectively, if scanned 1 year prior to autopsy. This study demonstrates the effectiveness of using an ordinal classification of positive or negative to interpret amyloid imaging at the patient level [25].…”

Section: [ 18 F] Av-45 or Florbetapirmentioning

confidence: 78%

Amyloid Imaging: Poised for Integration into Medical Practice

Anand

Sabbagh

2017

Neurotherapeutics

View full text Add to dashboard Cite

Amyloid imaging represents a significant advance as an adjunct in the diagnosis of Alzheimer's disease (AD) because it is the first imaging modality that identifies in vivo changes known to be associated with the pathogenesis. Initially, 11 C-PIB was developed, which was the prototype for many 18 F compounds, including florbetapir, florbetaben, and flutemetamol, among others. Despite the high sensitivity and specificity of amyloid imaging, it is not commonly used in clinical practice, mainly because it is not reimbursed under current Center for Medicare and Medicaid Services guidelines in the USA. To guide the field in who would be most appropriate for the utility of amyloid positron emission tomography, current studies are underway [Imaging Dementia Evidence for Amyloid Scanning (IDEAS) Study] that will inform the field on the utilization of amyloid positron emission tomography in clinical practice. With the advent of monoclonal antibodies that specifically target amyloid antibody, there is an interest, possibly a mandate, to screen potential treatment recipients to ensure that they are suitable for treatment. In this review, we summarize progress in the field to date.

show abstract

“…Also, a substantial number of papers on [ 11 C]PiB PET have been published in the European Journal of Nuclear Medicine and Molecular Imaging, which underscores the recognition of the importance of this topic by the Editorial Board of our Journal [8][9][10][11]. Importantly, several studies confirmed that the in vivo observations with [ 11 C]PiB PET are highly correlated with post-mortem assessment of amyloid pathology [12][13][14] [21,22].…”

mentioning

confidence: 80%

Appropriate use criteria for amyloid PET imaging cannot replace guidelines: On behalf of the European Association of Nuclear Medicine

Booij

Arbizu

Darcourt

et al. 2013

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study

Cited by 694 publications

References 19 publications

The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey

The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey

Amyloid Imaging: Poised for Integration into Medical Practice

Appropriate use criteria for amyloid PET imaging cannot replace guidelines: On behalf of the European Association of Nuclear Medicine

Contact Info

Product

Resources

About